The atezolizumab is directed against PD-L1 expressed on solid tumors including advanced/metastatic triple-negative breast cancer, resulting in disengagement of the interaction of PD-L1 and PD-1 to reactivate the T cell immune system [5,35]. The gene discussed is CD274; the disease is triple-negative breast carcinoma.